VANDA PHARMACEUTICALS INC. Marketable Securities, Unrealized Gain (Loss)
VANDA PHARMACEUTICALS INC. (VNDA) reported Marketable Securities, Unrealized Gain (Loss) of -$22.00 thousand for the 3-month period ending 2012-06-30, per its 10-Q filed 2012-08-03.
Discontinued › Income Statement › Other Income
us-gaap:MarketableSecuritiesUnrealizedGainLoss · last filed 2012-08-03
- VANDA PHARMACEUTICALS INC. marketable securities, unrealized gain (loss) for the quarter ending 2012-06-30 was -$22.00K.
- VANDA PHARMACEUTICALS INC. marketable securities, unrealized gain (loss) for the quarter ending 2011-06-30 was -$14.00K.
| Period end | Marketable Securities, Unrealized Gain (Loss) 3 month | Marketable Securities, Unrealized Gain (Loss) 6 month |
|---|---|---|
| 2012-06-30 | -$22.00K 10-Q · filed 2012-08-03 | -$16.00K 10-Q · filed 2012-08-03 |
| 2011-06-30 | -$14.00K 10-Q · filed 2012-08-03 | $83.00K 10-Q · filed 2012-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |